Anti-VEGF Injections: Protecting Your Retinal Vision
Understanding Anti-VEGF Therapy
Anti-VEGF therapy works by targeting a protein in the eye that drives abnormal blood vessel growth. Understanding what this protein does and why blocking it matters can help you feel more confident about your treatment plan.
VEGF stands for vascular endothelial growth factor, a protein your body produces naturally to help grow new blood vessels when they are needed. In certain eye conditions, cells in the retina produce too much VEGF. This triggers the growth of abnormal blood vessels inside the eye.
These abnormal vessels are fragile and prone to leaking fluid and blood into the retina, which is the thin layer of tissue at the back of the eye responsible for converting light into the signals your brain reads as vision. When fluid or blood collects in or under the retina, central vision becomes blurry, distorted, or blocked.
Anti-VEGF medications are designed to bind to the VEGF protein and block it from triggering abnormal blood vessel growth. By neutralizing excess VEGF, these drugs reduce leakage and help prevent new abnormal vessels from forming. This slows or stops damage to the retina and helps protect remaining vision.
The medication is delivered through an intravitreal injection, meaning it is placed directly into the vitreous, which is the gel-like substance filling the inside of the eye. Delivering the drug this way allows it to reach the retina at a much higher concentration than oral medication or eye drops could achieve.
Anti-VEGF therapy is used to treat several retinal conditions driven by abnormal VEGF activity. Your specialist will confirm whether this treatment is appropriate for your specific diagnosis.
- Wet (neovascular) age-related macular degeneration
- Diabetic macular edema, which is swelling in the center of the retina caused by diabetes
- Diabetic retinopathy, meaning damage to retinal blood vessels from long-term diabetes
- Macular edema following retinal vein occlusion, a blockage in the veins that drain the retina
- Myopic choroidal neovascularization, which is abnormal vessel growth related to severe nearsightedness
Who Is Affected and Why
Several conditions can lead to the kind of abnormal VEGF activity that requires treatment. Knowing the risk factors can help you and your specialist stay ahead of potential vision changes.
Wet AMD (age-related macular degeneration) is one of the most common reasons people receive anti-VEGF injections. It primarily affects people over age 50 and is responsible for the majority of AMD-related vision loss severe enough to affect daily function.
Risk factors for wet AMD include smoking, a family history of AMD, cardiovascular disease, and high blood pressure. Regular monitoring is especially important if any of these factors apply to you.
A significant portion of people with diabetes develop some form of diabetic retinopathy over time, and a portion of those develop vision-threatening complications that may require anti-VEGF treatment. Diabetic macular edema, in which fluid leaks into the center of the retina, is one of the leading causes of vision loss in working-age adults.
Uncontrolled blood sugar, high blood pressure, and a longer duration of diabetes all raise the risk of needing ongoing retinal treatment. Close coordination between your primary care physician and your eye specialist is an important part of managing diabetic eye disease.
Retinal vein occlusion, which occurs when one of the veins draining the retina becomes blocked, is more common in people with high blood pressure, diabetes, and glaucoma. Myopic choroidal neovascularization can affect younger adults with very high levels of nearsightedness.
In general, conditions that stress blood vessels throughout the body, including smoking, obesity, and cardiovascular disease, also increase the risk of developing retinal problems that may benefit from anti-VEGF therapy.
Available Anti-VEGF Medications
Several anti-VEGF medications are available today, and each has its own design, approved uses, and dosing schedule. Our retina specialists will recommend the medication that best fits your condition and treatment history.
The following anti-VEGF medications are currently FDA-approved for use in the eye. All work by blocking VEGF, but they differ in how they are structured and how long they remain active.
- Lucentis (ranibizumab): The first anti-VEGF medication approved specifically for eye use, approved for wet AMD, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, and myopic choroidal neovascularization. It is typically given every four weeks.
- Eylea (aflibercept): One of the most widely used anti-VEGF agents, approved for wet AMD, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. After an initial series of monthly injections, dosing may be extended to every four to eight weeks.
- Eylea HD (high-dose aflibercept): A higher-dose formulation of aflibercept designed for longer intervals between treatments. After initial monthly doses, some patients may go eight to sixteen weeks between injections.
- Vabysmo (faricimab): A bispecific antibody that targets two proteins, VEGF-A and angiopoietin-2. It is approved for wet AMD and diabetic macular edema, and clinical trials showed that about half of patients could extend their treatment interval to four months.
- Beovu (brolucizumab): Approved for wet AMD with dosing intervals of eight to twelve weeks after initial monthly loading doses. Your specialist will monitor for a rare risk of inflammation of blood vessels inside the eye with this medication.
Avastin (bevacizumab) was originally developed and FDA-approved to treat certain cancers. It is not FDA-approved for use in the eye, but it is widely used off-label by retina specialists to treat wet AMD, diabetic macular edema, and retinal vein occlusion.
Large clinical trials have shown that Avastin produces visual outcomes comparable to Lucentis for wet AMD. It is typically given every four to six weeks. Your retina specialist will discuss whether Avastin is the right choice for your individual situation.
Biosimilars are medications that are highly similar to an already approved biologic drug. Two biosimilars of Lucentis have been approved in the United States, Byooviz (ranibizumab-nuna) and Cimerli (ranibizumab-eqrn), both approved for the same eye conditions as Lucentis. These biosimilars expand the options available to patients and their specialists when planning treatment.
What to Expect During Treatment
Knowing what happens before, during, and after an injection can help reduce anxiety and make your appointments go smoothly. Most patients find that the experience becomes much more manageable after the first visit.
Before your first injection, your retina specialist will perform a thorough eye examination. This typically includes optical coherence tomography (OCT), which is a scan that produces detailed cross-section images of the retina, and sometimes fluorescein angiography, a test using a special dye and camera to photograph blood flow in the retina.
On the day of the injection, the eye is numbed with anesthetic drops or a small amount of numbing medicine around the eye. The surface of the eye is then cleaned with an antiseptic solution to reduce the risk of infection.
The actual injection takes only a few seconds. A very fine needle is used to place a small amount of medication through the white part of the eye and into the vitreous cavity. Most patients feel pressure rather than sharp pain, though some mild discomfort is normal.
You typically do not see the needle during the procedure. Your specialist may briefly check your eye afterward to confirm everything looks as expected before you leave.
Mild redness, irritation, or a gritty feeling in the eye is common for a day or two following the injection. Some patients notice small floaters or a bubble in their vision, which usually clears within a few days.
Your specialist will give you instructions about any prescribed eye drops and let you know when to return for your next visit. It is important to follow those instructions closely to support healing and reduce any risk of complications.
Anti-VEGF treatment typically begins with a loading phase of monthly injections for the first three months. After that, the schedule depends on how your eye responds. Many specialists use a treat-and-extend approach, gradually increasing the time between injections as long as the retina stays stable.
Some patients eventually go two, three, or even four months between treatments. Others need more frequent injections to keep their condition under control. Anti-VEGF therapy is generally an ongoing commitment, and sticking with your recommended schedule is one of the most important things you can do to protect your vision over time.
Results and Effectiveness
Anti-VEGF therapy has transformed the outlook for people with serious retinal conditions. Understanding what results are realistic helps set appropriate expectations from the start.
Anti-VEGF treatment improves vision in roughly one out of three people who receive it. For the large majority, approximately nine out of ten patients, treatment stabilizes vision and prevents further decline. Before anti-VEGF therapy became available, most people with wet AMD faced progressive central vision loss with few options to slow it.
Today, patients have a much better chance of maintaining the central vision needed to read, drive, recognize faces, and carry out daily activities. The earlier treatment begins, the more vision there is to preserve.
The benefits of anti-VEGF therapy depend on receiving injections on schedule. Missing appointments or stopping treatment early can allow the disease to become active again, and fluid or blood may return to the retina. Vision gains that took months of careful treatment to achieve can be lost relatively quickly if injections are interrupted.
If keeping up with your treatment schedule becomes difficult, speak with your specialist. Newer medications with longer-lasting effects, such as Eylea HD and Vabysmo, may reduce the number of visits needed while still keeping the disease well controlled.
Living with Anti-VEGF Treatment
Managing an ongoing retinal condition involves more than just your clinic appointments. There are practical steps you can take at home and in daily life to support your eye health between visits.
Between appointments, you can keep watch on your own central vision using an Amsler grid. This is a simple chart with a grid of straight lines and a central dot that you look at one eye at a time. Changes such as wavy lines, missing areas, or dark spots in the grid can be an early sign that something has changed in the retina.
Your retina specialist can provide an Amsler grid and show you how to use it correctly. If you notice any new distortion when checking the grid, contact your specialist promptly rather than waiting for your next scheduled visit.
Receiving ongoing eye injections can feel overwhelming, and it is completely normal to feel anxious about the procedure, especially in the beginning. Many patients find that the anticipation is more uncomfortable than the injection itself, and that anxiety tends to decrease after the first few appointments.
If anxiety remains a concern, let your specialist know. They may be able to offer additional numbing or other strategies to improve your comfort. Living with a chronic retinal condition also means adapting to a regular cycle of medical visits, and planning ahead with transportation and scheduling can make the routine feel more manageable over time.
While anti-VEGF injections treat the disease directly, certain habits support overall eye and vascular health alongside your medical treatment. These choices will not replace injections, but they can play a meaningful supporting role.
- Avoiding smoking, since smoking significantly increases the risk of AMD progression
- Managing blood sugar carefully if you have diabetes
- Controlling blood pressure and cholesterol with your primary care physician's guidance
- Eating a balanced diet rich in leafy greens, fish, and other nutrient-dense foods
- Wearing sunglasses that block ultraviolet light when outdoors
When to Seek Immediate Care
Knowing when a symptom needs urgent attention can make a real difference in protecting your vision. Some warning signs require a same-day response, while others call for prompt contact with your specialist.
Certain symptoms should never be ignored or waited on. If you experience any of the following, contact your retina specialist immediately or go to the emergency room right away.
- A sudden increase in floaters, which are spots or strands drifting across your vision
- Flashes of light in one or both eyes
- A shadow, curtain, or dark area spreading across your field of vision
- Sudden loss of vision in one eye
- Significant eye pain, redness, or light sensitivity after an injection
Some changes in retinal disease happen gradually and can be easy to overlook from day to day. Contact your retina specialist if you notice straight lines appearing wavy or bent, a growing blank or dark spot in the center of your vision, increasing difficulty reading or recognizing faces, or any new distortion when checking your Amsler grid.
Early detection of disease activity allows your specialist to adjust treatment before significant vision is lost. It is always better to report a change that turns out to be minor than to delay reporting something that needs prompt attention.
Even when your vision feels stable, regular visits allow your retina specialist to detect subtle changes using OCT imaging and other diagnostic tools. These changes may not be noticeable to you but can signal that the disease is becoming active again beneath the surface.
Keeping all scheduled appointments, even when you feel well, is essential for long-term vision protection. Consistent monitoring is what makes it possible to catch problems early and respond before meaningful vision is at risk.
Frequently Asked Questions
These answers address common questions our patients bring to their appointments and offer practical guidance on decisions you may face during treatment.
Most injection appointments take about fifteen to thirty minutes from start to finish, including preparation and a brief check afterward. The injection itself takes only a few seconds, with the rest of the time devoted to numbing the eye, cleaning the surface, and confirming everything looks normal before you leave. Many patients are surprised at how efficient the process is once they have been through it a few times. You may want to arrange a ride home for your first appointment, as some patients notice temporarily blurred vision from the numbing drops.
In some cases, treatment can partially improve vision, particularly when it begins early before significant retinal damage has occurred. However, the primary goal of anti-VEGF therapy is to stabilize vision and stop further loss rather than to restore what has already been permanently affected. Retinal tissue that has been scarred or damaged may not recover fully. This is one of the most important reasons to begin treatment promptly after diagnosis and to keep up with the recommended schedule once you start.
The most common side effects are mild and short-lived, including redness on the white of the eye, a gritty or scratchy sensation, mild soreness, and temporary floaters that typically clear within a few days. Serious complications are uncommon but can include infection inside the eye (called endophthalmitis), retinal detachment, or a temporary rise in eye pressure. Your specialist follows careful sterile technique to minimize these risks at every appointment. Any sudden increase in pain, a significant change in vision, or worsening redness after an injection should be reported right away rather than monitored at home.
Treatment duration varies considerably from person to person and depends on how the retina responds over time. Some patients are able to gradually extend the time between injections and may eventually pause treatment if the disease remains inactive for an extended period. Others need ongoing injections to keep their condition well controlled. Rather than planning for a fixed endpoint, the most helpful approach is to work closely with your specialist and let the retina's response guide each decision about timing and frequency.
All anti-VEGF medications share the same core function of blocking VEGF to reduce abnormal vessel activity, but they differ in molecular design, how long they stay active in the eye, and which conditions they are approved to treat. For example, Vabysmo targets an additional protein called angiopoietin-2 in addition to VEGF, and Eylea HD uses a higher dose designed to extend intervals between visits. The choice of medication is based on your specific diagnosis, your treatment history, how your eye has responded in the past, and your specialist's clinical judgment. Switching medications over time is also common and not a cause for concern.
Expert Retinal Care in Rhode Island
Rhode Island Eye Institute is home to a team of fellowship-trained retina specialists, including Dr. Gaurav Gupta and Dr. Pranjal Thakuria, who bring deep expertise in anti-VEGF therapy and the full range of retinal conditions it treats. We use advanced diagnostic imaging and individualized treatment planning to help each patient protect the vision that matters most to them. If you are managing a retinal condition or have been told you may need anti-VEGF injections, we welcome the opportunity to care for you at any of our convenient locations across Rhode Island.